Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Nanoform, Audiocast with teleconference, Q3'24

By Inderes11/18/2024, 1:00 PM
Nanoform Finland

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Henry von Hartmann
00:06 - 01:09

Good afternoon all, and a warm welcome to Nanoform's third Quarter 2024 report presentation. My name is Henry von Hartmann, and I'm your Director of Investor Relations. Today our CEO, Edward Hæggström; CFO, Albert Hæggström; Chief Development Officer, Peter Hänninen; and Chief Commercial Officer, Christian Jones, will present to you. This presentation is webcast through financial hearings, and there is also the possibility to call in and listen by phone. The presentation slides are shown throughout the webcast and they can also be found on our webpage in the investor section. After the presentation, we will hold a Q&A and it's possible to call in and ask questions. We will start today with an introduction to Nanoform, followed by the financials, then our product kernels, and we will conclude with commercial aspects.

Edward Hæggström
01:11 - 12:07

Thank you, Henry. And welcome also on my behalf. Just up front, a few things to note. We're going to talk about a record number of POCs. We're going to talk about deal negotiations, which show the relevance we have in the industry. We're going to talk about registration batches, which show that we can meet those deals. Once signed, we will show that the insourcing of the GMP QC lab has significantly increased the gross margin. And we will talk, of course, about nano Enzalutamide and nano Apalutamide, the two blockbuster innovations that are our sharpest focus right now. You will also see faces from very senior leaders in the industry. Again, a testament to the fact that our relevance is growing as we move forward. There will probably also be talk about Mosaic, which is a web of deals that we are starting to work on. Next slide please. Here we can see our three key strategies. It really has three pillars: one, all active pharmaceutical ingredients should be STARMAP. So basically our AI is able to give them a ranking on how well we will perform and then how we should set the knobs on the machine. Nanoform works with customers and partners to enable both novel and existing molecules to become new and improved medicines. This is important. We do stuff in-house, we do stuff with development partners, and we do stuff with commercialization partners. The third box illustrates how Nanoform demonstrates its power in a conservative industry. We create up to a dozen product kernels here. The important part is that we need to drive the development and the uptake of the platforms. Therefore, we do this. We partner out in order to not have to take all the costs ourselves. Next, please. Here you can see the four platforms for small molecules called CESS and for large molecules called Bio for formulation, along with the AI platform. We already spoke about STARMAP. The Nanoform is where we really make sure that the APIs we have Nanoform, then go into a formulation which drives the biological response. On the small molecule side, you can see that bioavailability continues to be very important. Next please. Here you can see the bioavailability. The idea is that when you Nanoform, you take coarse powder and make it very fine. And the reason why this is effective is that you increase the active surface area. Next, please. Here is a Biologics slide. In the entire universe of biologics, there are very few technologies, and you can see that our Nanoform creates small particles which allow us to play this game with high concentration. It allows us to use, for instance, small needles. It allows us to use moderate injection forces, and most importantly, it opens up new commercial strategies for people playing in this universe. You can see in the middle a spray dried form, which is one of the key contenders, and then you can see lyophilised flakes to the right. Lyophilization is very cold. Think -60. Spray drying is warm or hot. Think 60 to 100 degrees and we are then in the Goldilocks zone where it's neither hot nor cold. Next, please. Here you can see the simplified value chain. So basically, we work with large pharmaceutical companies, mid-sized firms, and biotech companies; we get the bulk API in with the nano format. They own the material; we get paid for service, we get paid to make material, and then we get paid for technology access or for royalty-based pricing later on. Next, please. Here you can see five boxes with highlights from Q3. As mentioned, we had a new quarterly record on the customer non-GMP project side. This is, of course, important because it means that we learn about new APIs, and we also get the opportunity to move them into GMP projects. The revenue growth is back. Albert will talk more about this. Then you can see in the third box, Takeda. Takeda is a big company in the biologics space. And of course, here we are very, very happy for the endorsement we received and also to be able to bring projects forward and, of course, later on into GMP. We can see in box number four that we have continued to manufacture GMP materials for the registration batches and the pivotal studies. And then the last box, we have been working a lot this year and this quarter on collecting term sheets, letters of intent to really build up these options for deals to be made around the product kernels. Next slide please. With this, I hand over to Albert. Albert, please. Thank you Edouard. If we start, as Edouard said, you can see that we signed a record number of deals in the quarter. So of course the quarters fluctuate from quarter to quarter. But we clearly see that we continue to be at a 20-plus level. And we see the interest growing. And this was also helped by the fact that the biologics side is now starting to pick up. We clearly see growth in the number of projects in the future quarters and years. To the right-hand side, you can see the rolling 12-month numbers. Of course, the important thing is that we are also working and expect the proportion of GMP contracts to overall projects to increase in the coming years. If we then look at the revenue, we are still at quite low numbers. But you can see that after six quarters of negative year-on-year growth, we now have a positive year-on-year growth. One crucial point to highlight is that this was the first time we observed sequential growth from the second to the third quarter, even though typically the third quarter is lower than the second quarter due to July holidays when we don't book any revenue. But despite this situation, we booked more revenue in the third quarter than in the second. We truly believe that after this one and a half year period of negative growth, we are back in growth mode and anticipate that this will continue in the coming quarters and years. We obtained the Fimea license in August, and already in the recent quarters, we have been able to use outsourced GMP QC analysis more efficiently. But now from the fourth quarter, going forward, this will drop further. And this will, of course, help the gross margin to go back to a level that we target, meaning above 90%. This will improve the gross profit further. So when the top-line growth increases and the gross margin is above 90%, That means that you get a direct impact from the growing top line to the bottom line. And here you can see all the sorts of analysis, the different kinds of analysis that need to be performed when you do a GMP campaign. So up until September, more or less, all of it was outsourced. Now we have insourced it, and we only use our outsourcing partners as a sort of backup source if needed or if something were to happen. But basically everything has been insourced. This, of course, also lowers the shipping cost. It all lowers the shipping cost. It also improves flexibility. We can do it in-house. People walk 50m or 5m and they get faster results because of the closer proximity to resources. So we improve the speed of interaction between the teams. And of course, this also means that our service offering is broader because we don't have to utilize outsourced resources, so clients can ask us to do it in-house. And that's a positive thing. If we then look at the operating free cash flow, the positive trend continues and we expect it to continue in the coming quarters and years. At the end of the third quarter, Nanoform had $46 million in cash and short-term government bonds, T-bills. And we had no debt. So we have a strong balance sheet. And this is, of course, important for us. Also, when we now negotiate around deals, it's important that the counterparties understand that we are well-funded, we have a strong balance sheet, and that is a good thing. Final slide is around near-term business targets. Here you can see the traction so far, with the number of customer projects we target to sign more this year than last year. Uh, we also target to improve the cash flow this year versus last year. And we still target to sign at least one license or commercial supply agreement during this year. Uh, we have already signed half a dozen term sheets, or we have already received half a dozen term sheets. The first Letter of Intent (LOI) has been signed. And here we can say that for us, these are deals and agreements. When we work together with the commercialization partner to put millions of tablets on the market around the world for the coming five, 10, or 15 years, it's important for us to strike good deals, rather than focusing on whether they are signed in December or January. So what we now say is that we will sign several deals on several products during the coming quarters. And with this, I hand over to Peter to talk more about the product kernels. Thank you, Albert.

Peter Hänninen
12:07 - 16:29

To start and to reiterate as well, in order for us to further accelerate the adoption of our technology offering by the industry, we are developing internally a number of these nano-enabled reformulations. And this is really to show the global pharmaceutical industry, in practice, what our technology can enable for their products across a range of delivery routes and for both small and large molecules. And each of these also has the potential to become a commercially attractive partnering opportunity for us, in line with what we are already seeing. And as a reminder, amorphous solid dispersions, or ASDs as they are commonly known, are really the technology that has enabled a past generation of poorly soluble drugs and ASD-based medicines. There is a group of approximately 50 products now on the market, selling for an estimated $50 billion annually, and with hundreds of products estimated to be in the development pipeline. As amorphous materials are notoriously unstable, they require a high amount of polymers to stabilize the drug product, and this means that in some cases, less than 10% of the content in a pill is actually the drug substance that benefits the patient, while the rest is composed of polymers and other excipients. And for the patient, this means large or many tablets that need to be taken. What we are doing with our Nanocrystalline formulation platform is to enable significantly higher drug loads in the product, and for the patient, this means smaller pills and a reduced pill burden. And we believe our technology can provide an attractive alternative both for the originators and value-added medicine companies alike. And this is also what we are seeing in practice at the moment. As we reported today, we are very pleased that the nano Enzalutamide and Nano Apalutamide projects have attracted clear partnering interest, as evidenced by the term sheets received. And as Albert earlier mentioned, we are now in the process of making sure that we can get the best possible partners for the commercialization of these assets, and expect to sign several deals on several of these in the coming quarters. For nano Enzalutamide, we look forward to the pivotal trial. Of course, that is planned to start in the first quarter of next year. And as has been mentioned, we're currently manufacturing the material for this. In parallel, this morning we also reported that we were pleased with the results from an in vivo pharmacokinetic study in which we compared our crystalline nano Apalutamide tablet prototypes to the originator presentation. These results give us confidence in choosing the lead prototypes, and should also accelerate interest in this opportunity among potential partners. Based on our earlier experience with nano Enzalutamide and following further optimization of the formulation, we believe the next step should be a pilot study in humans to close out on my part. As you can see, during the past 12 months, we have been able, in short order, to build momentum in this space and are, in addition to nano Enzalutamide and nano Apalutamide, working on a number of additional product kernels already. And these are overall, I would say, progressing very well. We cannot yet disclose the identity of all of these for IP and commercial reasons, but we will, of course, provide updates when appropriate. Following the progress of nano Enzalutamide and nano Apalutamide, we aim to partner with these for commercialization in the coming few years. And now I will turn over to Christian.

Christian Jones
16:30 - 26:08

Thank you very much, Peter. It's a pleasure to talk to you today about our commercial function and the activity that we've seen in the last quarter, quarter three, but also throughout the year. Um, we're going to discuss the work we've been doing with our customers and partners to help enable their novel and existing molecules to become new and improved medicines. So here we're typically talking about innovative pharma from the preclinical stage all the way through to life cycle management of their assets. As you can see on this slide, it's a very busy slide. And it's busy for one reason: because we've been busy. At the top left, we have Dr. Ajit Shetty, former chairman of Janssen, and Dr. Makarand Jawadekar, a former Pfizer Global executive, visiting our facilities earlier this year. Um, to be able to attract people like this to our organization says something about the work that we're doing. And next to them, we have a visit that was carried out by AstraZeneca, and we were delighted to welcome Sophie and Jeff from AstraZeneca, as Jeff is the BD director for their innovation growth area, and Sophie is an R&D director within AstraZeneca. To the right of that, you see us in Portugal recently, a couple of weeks ago, visiting our partners Bluepharma. Enzalutamide and Bluepharma are the drug product manufacturing partners as part of that consortium. And then on the right, this is a photo taken from last week when we were in Japan. Um, we had a packed audience of a Japanese delegation, about 300 strong in that room. A senior scientific and commercial representation from the major pharma companies in Japan. Um, very interested in the expansion of Nanoform technology into this marketplace and the innovation that our technology can deliver for both the domestic market and also for the international markets, for Japanese pharma companies. Bottom left, you will see Doctor Andreas Liebminger, the head of plasma-derived therapy pharmaceutical sciences at Takeda, who presented on Nanoform technology back in May of this year and discussed the opportunity for high concentration biologics to be achieved with the Nanoform bio platform. This was a pivotal moment for us this year, and it has since garnered significant traction in the marketplace around Nanoform, around what we are doing, the offerings that we can sell and partner. And we have seen a lot of interest around how Nanoform can help to enable high concentration biological products, take IV products and convert them to subcutaneous injection, take a twenty-two injection-a-day product and convert it to a single injection a day. The industry sees significant value in this. And then at the same conference, we had Christian Schneider from Celanese presenting on our technology. And to the right you'll see some of the other conferences that we've been active in, CPhI was held in early October and was a record key for Nanoform. Um, we saw 120 pre-arranged meetings. Now, I'll put this into perspective. The previous year we had 54, and the year before that, 40. So to go from, you know, a gradual increase of pre-arranged meetings to suddenly 120, something has changed and people are starting to see the value of what Nanoform is doing. We've seen significant interest in our technology, as case studies exemplified, that Peter mentioned Enzalutamide and Apalutamide. Discussions around these products were held at CPhI, but also discussions around early development pipelines and how Nanoform could actually enable a single tablet for a pharma company to be launched where no generics could ever copy that tablet. And that is valuable. We also saw at the Pod conference a fantastic event where Nanoform really took center stage, and the opening of that conference was held by Bob Langer, who opens the conference each year, followed by a presentation by Anand Subramanian, SVP at Lilly, and then by Nanoform. And we had an audience of about 1,000 people in the room in the Grand Ballroom in Boston, and not one person got up to leave. And I was very proud to see the company presenting on that stage. And the following day, I was privileged to chair a panel discussion with GSK, Takeda, and others around high concentration biologics. So a theme has certainly started to emerge. It's the value that Nanoform can provide in enhancing bioavailability and increasing drug load for small molecules, as well as increasing drug load and patient convenience for biologics. So if we move to the next slide, you'll see that we've had a positive increase in the number of customers in the last nine months. But we've also seen an increase in the number of projects with 17 projects added. And as Albert mentioned, a record number in this last quarter with 12 non-GMP projects signed. This just gives you an overview of the types of therapy areas that we're working on, from preclinical all the way through to marketed products. And we've shown this information previously in previous reports. But the next slide that I'm going to show you provides a bit more detail around some of the active programs we have ongoing and some of their formulation challenges. And these are some of the reasons that pharma companies come to Nanoform. So you can see here that we work with mid-sized pharma and biotech all the way through to large pharma. We work across a variety of different therapeutic areas, with oncology, infectious disease, respiratory, and CNS being areas called out here. But the formulation challenges, such as drug load, are a common challenge. The fine particle fraction, related to the delivery to the lung, is another area where our particles are seen to have increased benefits, particularly in long-acting injectables and sustained release profiles, among other areas. But what you also see from this slide is that we have a growing proportion of projects in the large molecule space, and I would say that this has really taken off in the last year. Interest in our large molecule platform has surged significantly. The current companies in the marketplace servicing this very challenging delivery mechanism include Halozyme. And people are really seeing Nanoform technology as potentially a superior alternative to deliver more patient-centric medicines. And if we move to the next slide, you can see that the year may be drawing to a close. But we're still very, very busy. Um, next week we will be at the CIB conference in Stockholm, um, followed by the NBS conference in Oslo, uh, followed by a conference in Manchester on the pharma partnering side and other activities throughout the year, leading into a very busy start to next year and going forward, um, as we as we progress. But I think the message is that there is a significant amount of commercial interest in Nanoform technology. Um, it's really ramped up, um, throughout this year. Q3 saw a significant uptick in the number of projects. Um, and based on the level of interaction that we've seen in Q3 and into Q4, we should see some significant results coming forward in terms of sales and future business as we move forward. And I will end the presentation here and open up for Q&A.

Operator
26:14 - 26:34

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound six on your telephone keypad. The next question comes from Christopher from SEB. Please go ahead.

Christopher Udeh
26:36 - 27:22

Hi there, Christopher Udeh from SEB. Thank you for taking my questions. Um, I guess my first question is just in terms of operational KPIs to track. Until this quarter, you used to provide information on the number of proposals issued. Um, that's no longer available. Uh, what can you say about that? And, um, you know, just trying to get a sense of what your confidence is in hitting your 2024 target. Um, and, you know, the sort of, uh, carrying the momentum towards that acceleration of projects, assigning growth. So that's my first question. We work across a variety of different therapeutic areas, oncology, infectious disease, respiratory, and CNS being areas called out here.

Edward Hæggström
27:23 - 27:38

Christopher Edward here. Uh, we are, uh, business as usual here. Uh, the proposals issued, uh, are on a good level. And, uh, we see momentum carrying into the next year. Christian, do you want to say something more?

Christian Jones
27:39 - 28:14

Yes. I think, um, we're focusing much more, um, perhaps in this presentation, on the deals that we have upcoming, um, and the sort of mosaic around, um, how we might want to sort of structure those deals. Um, and the level of commercial activity has dramatically increased. Um, and so, you know, we just didn't think it was that relevant to include that information in the report. Um, but you know, what's going to speak is the numbers that we deliver, and you'll see that at the end of the year.

Christopher Udeh
28:17 - 28:58

Uh, we are, uh, business as usual here. Uh, we are, uh, conducting business as usual here. Uh, we are, uh, business as usual here. And, um, so then, uh, I guess my next question would be sort of around the term sheets versus the projects. So you mentioned that six have been issued. Uh, and several projects are actively being negotiated, I guess. So, is the ratio basically one more or less per project, or are there any that have multiple projects? And, you know, can you say if Nanoform's Enzalutamide has more than one term sheet that's been issued for it? Uh, that's the next question. Uh, we are, uh, business as usual here.

Edward Hæggström
28:59 - 29:41

So, Edward here, Christopher, this is a convoluted question that you posed, but let me see if I can answer in a simple way. Uh, the mechanism for going from Proof of Concept (PoC) to GMP, I see that as one continuous process. Then I see the product kernel negotiation. The deal negotiations are considered a different process. Of course, the reason why we can have these negotiations is the work we have done before and the networks we have put in place. Then you asked whether there are more than one taker for each of these opportunities. The answer is yes. And that's, of course, what we want to do. We want to create an auction-like situation where there is competitive interest from multiple parties in our offerings.

Peter Hänninen
29:41 - 30:33

No. Exactly. So this process typically moves in a fashion where, first you have non-confidential discussions. First, you have non-confidential discussions, then you have some confidential discussions. There is an expression of interest which may be followed by a term sheet. And then the discussion sort of moves forward from there. And then with that in mind, the further the projects have advanced, the more term sheets there are on the table and vice versa. So the short answer to the question is that, yes, there are multiple term sheets for Enzalutamide. And we are progressing all of these processes in, I would say, quite a controlled way to be able to extract as much value from them as possible.

Edward Hæggström
30:34 - 31:33

If I answer a little bit differently. Regarding all the projects, So not only nano Enzalutamide and nano Apalutamide, but also the other kernels where we have already initiated discussions, we expect to have multiple partners for different regions. So if you think about Europe, you have five big countries in Europe and then the wider European region. So we could have local champions and then we could have a European champion. You have the US, where you could have one partner or several partners. You have Japan, you have the Middle East and Africa, and you have Asia. So, all these regions have different discussions, and all the products have different discussions. So we expect to get, as we have said, several signed agreements on several products in the coming quarters.

Christopher Udeh
31:36 - 32:03

So this process typically moves in a fashion where first you have non-confidential discussions. Great. So this process typically moves in a fashion where, uh, first you have, uh, non-confidential. And then, um, all right, so you have a slide now comparing where you are today versus the IPO. Um, yeah, it's pretty fantastic progress. I think, uh, operationally. Um, so, you know, we're basically almost five years since the IPO. So how well differentiated are you today versus alternatives that are not necessarily yet well established, but sort of both on the CESS and the bio side of things?

Edward Hæggström
32:06 - 32:11

Uh, can I ask whether you mean from a technology point of view, or how do you mean?

Christopher Udeh
32:13 - 32:21

Yeah, well, I mean, I definitely was thinking of the technology point of view. I don't know if there are other aspects that you think are worth addressing. That'd be interesting to hear too.

Edward Hæggström
32:21 - 35:12

So this process typically moves in a fashion where, first, you have non-confidential discussions. So let me answer you in two ways. From a technology point of view, I think we are now, after five years of commercial efforts, well differentiated. Then, when it comes to commercial differentiation, I think, as we said at the beginning of this call, it seems that bioavailability and high concentration are now crystallizing out. That doesn't mean that it's the only thing we do, but those are core drivers for what was described here as having the ability to go into a one-pill strategy or so forth. Maybe Christian, you want to say something else if I, if I, if I continue directly from there. So I would put it like this. When we did the IPO, we had a few lines and potentially 100 or so hours on the lines. Now we are at 10,000 hours on the lines. We have a very robust technology. We have done 100 projects and at the beginning, or at the IPO, we were mainly thinking about whether we could Nanoform them and put them on the line. Can we get certain particles? Now we have a lot of knowledge. What can we do? We have come up with a new way to produce these crystallized particles, alternatives for ASDs. And we have concretely produced tablets that are much, much smaller and in fewer quantities than what the big pharma companies have been able to achieve. So think about it. You have a blockbuster product, several blockbuster products on the market where you need to take many pills or a really, really big pill that's difficult to swallow. This development was achieved over 5 or 10 years, leveraging the resources of a large pharmaceutical company to launch a blockbuster. We have been able to do something that nobody has been able to do before: create, for example, one pill for 160mg nano Enzalutamide or one pill for 240mg nano Apalutamide. So, 10,000 hours on the line, robust process, being able to make products that nobody has been able to make before. And this is sort of the key. So we have built up, and now we have 20 lines. We have the Fimea licenses and so forth. And we have a brand which is really recognized in the industry. Uh, so we are a very different company. But, Christian, you have been on the journey also. So how would you answer this very interesting question?

Unknown 1
35:12 - 35:13

Well, I.

Christian Jones
35:13 - 37:49

Think, um, you know, when we first started out, people were interested, um, there was speculative interest around what we were doing. I think we started to show the value of what we can do, particularly with these examples of Enzalutamide and Apalutamide, and people realize that this is a technology to be taken seriously, especially when we say we're going to put a product on the market by 2027. Um, you know, the pharma industry is all about risk for Nanoform. It's all about being able to prove that we are not a risk, that we can actually create significant value for our partners. By being able to discuss putting products on the market and actually achieving it, we demonstrate to the industry that this technology is something to be taken seriously. Um, and also, you know, since over the last few years we've scaled the technology, and we're now at production rates that are capable of producing ten metric tons per year for a single line. And that gives huge confidence to our pharma partners, as they discuss the global population that needs to be provided with their medicine. So, you know, we are building that confidence. And I think being able to show the value and demonstrate it on products allows partners to see us differently. And added to this, when we think about the small molecule platform, there is also a parallel development. And this is not something we necessarily set out to do, but as a function of our technology inherently built-in, it is green, right? It's a green technology. And um, you know, when you compare that to the other technologies available to try and achieve the same, same or something similar, it may not be as good. These are not green technologies. You know, spray drying is a very carbon-heavy technology. Um, and we're able to get better results, with similar bioavailability but much better drug loading, and do it in a green way. And that very much aligns with the major pharma companies we are working with. And as you can see from this slide here, we have built relationships with 11 major pharma companies now, some of which have allowed us to use their logos on the right-hand side, along with many other companies. Um, we're starting to really get the brand visibility, recognition, and credibility out there. I hope that answers your question, Chris.

Operator
38:06 - 38:10

The next question comes from Sami Karkamis from Danske Bank. Please go ahead.

Sami Karkamis
38:14 - 38:34

Hi, I would like to start with a few questions regarding your customer project pipeline. Firstly, you signed 12 non-GMP deals in the third quarter. Is this a new normal or should we assume a return to a more typical level from the fourth quarter onwards?

Edward Hæggström
38:36 - 39:03

Sami, you ask us to have a crystal ball. I think that the best estimation for where we are going is to take a moving average of what we have. Albert, do you want to add something? I think what we have said is we expect to see growth in the coming quarters and years, and that is also related to the number of projects. But of course, there will still be fluctuations between the quarters.

Sami Karkamis
39:07 - 39:23

It's all about being able to prove that we are not a risk, that we actually can create significant value for our partners. And then my second question would be, do you see possibilities to make new GMP deals over the next two quarters? Which projects would have the potential to move into a more commercial phase?

Edward Hæggström
39:26 - 40:28

Albert, do you want to take that one? I think we are not giving guidance on how many projects we are going to sign for the coming two quarters, but what we expect is to see more GMP projects coming in the upcoming quarters and years. And if you think about these projects, for example, here, many of them are such that they could progress to GMP. And this is one example that we have been able to publicly mention. Of course, if these are great, then they could move quite quickly to GMP. But of course also around all these product kernels that we develop, and when we sign deals, they will also become GMP projects in the coming quarters and years.

Sami Karkamis
40:32 - 41:01

Albert, do you want to take that one? Albert, do you want to take that one? And then I would have a couple of questions regarding deal-making around your seven product kernels. Firstly, you have so far received six term sheets following approximately 100 meetings. Do you expect to receive a significant number of additional term sheets based on these meetings, or do you actually need to have more meetings with new potential clients to increase the number of term sheets?

Edward Hæggström
41:01 - 41:29

No. So what we have done there is that we have had over 100 meetings, and we expect to get more term sheets and more alliances and more deals on multiple or several products in the coming quarters. So remember, if you take 1 to 3 or more products, we will get many term sheets and sign several deals on each of these in the coming quarters. That's the target.

Sami Karkamis
41:32 - 41:33

Yeah. So just.

Edward Hæggström
41:33 - 41:35

Many of the, many of the.

Sami Karkamis
41:35 - 41:35

Actually.

Edward Hæggström
41:36 - 41:44

Many of the meetings have been held and we will still hold many meetings to come in the coming months and quarters.

Sami Karkamis
41:46 - 42:00

Yeah. But like, you have enough, um, let's say critical mass in the prospect pipeline that you just need to work through that pipeline in order to get more letters of intent.

Edward Hæggström
42:00 - 42:08

We already have the critical mass, but of course, we will continue to talk with the potential partners.

Sami Karkamis
42:12 - 42:34

Albert, do you want to take that one? And then maybe finally, can you comment on the quality of term sheets that you have received? Are these, broadly speaking, acceptable to you, or do you need, let's say, higher quality term sheets in order to grow the number of alliances and actually reach contracts with customers?

Edward Hæggström
42:35 - 42:48

These are all serious players, so they don't engage in low quality endeavors. They are all quality term sheets. And these are serious pharma companies and they only engage in quality work. And that is also what we expect.

Unknown 1
42:51 - 42:52

Yeah.

Sami Karkamis
42:52 - 43:04

And how are the commercial terms and conditions looking from your perspective? I mean, are they in line with your assumptions or are there any sort of surprises?

Edward Hæggström
43:04 - 43:45

They are in line with our assumptions. And of course, it's always a negotiation. And the positive thing is that because we have so many interested potential partners, that means we will get lots of term sheets. We have already received several, and that means we will be able to strike fair deals. Fair is the right word. We are not trying to maximize any one single deal. We are trying to sign many fair deals where we add value and get paid for it.

Sami Karkamis
43:48 - 43:51

Okay. Yeah. I don't have any further questions.

Operator
43:57 - 44:01

The next question comes from Christian Glennie from Stifel. Please go ahead.

Christian Glennie
44:05 - 44:45

Hi, guys. Thanks for taking the questions. Um, the 12 projects signed in the third quarter. Um, just trying to understand the dynamics behind that. I mean, historically, you've pointed out biotech funding weaknesses and other factors as reasons for why previous quarters may have been low in biotech funding. That environment has maybe improved a little bit, but not significantly. Um, so what has driven that sort of significant step up in the third quarter, please. And then maybe if you can say anything about the mix between small molecules and biologics in those 12.

Edward Hæggström
44:46 - 45:24

So maybe we will let Christian take this, but in a sort of short way of answering, uh, it's clear that, uh, our brand has continued to grow. And now it has generated this kind of surge, which we are, of course, very happy about. Then, when it comes to the mix, I think that what you see on the current slide shows something about the mix. We started from only small molecules. And then now we have this ratio that you can count here. And I think that the ratio of the large molecules will continue to increase on this slide. But maybe Christian from the trenches can provide more insight.

Christian Jones
45:24 - 47:22

Yeah, I would say, um, you're absolutely right, Christian. It's not like biotech funding has suddenly, you know, taken off. Um, however, I think what we had started to do, maybe a year to even 18 months ago, was to really entrench and develop our relationships with our major pharma partners because they have deeper and broader pipelines and have more funding available to support the development of their projects. And that's really paid off because from those relationships, we've been able to engage with some major pharma companies that have several projects they want to entrust to us at any given time. And that's helped. And of course, um, we hope to see that continue. Um, as we continue working on those projects with them. So that's, I think, that's why potentially you've started to see an uplift. We do sense that the biotech market seems to be moving more positively. Um, some of the engagements that we've had over the past 12 months or so were maybe we've had projects on hold. Um, some of those biotechs have suddenly secured funding, and therefore, they're able to work with Nanoform. Um, but, um, I think it's a combination of that plus the efforts and the focus that we've placed on trying to win business with major pharma as well. And then to the large molecule-small molecule split. Um, I would say still slightly more on the small molecule side. Um, but there's a growing interest in the large molecule, um, area. And so, um, you know what this pipeline will look like in 12 months from now, I don't know, but, um, large molecules is certainly a very, very hot, uh, area. Um, for us. And people see our technology as highly attractive to enable better products.

Edward Hæggström
47:22 - 47:24

Also remember that.

Unknown 1
47:24 - 47:24

Uh.

Edward Hæggström
47:24 - 48:42

Our target is to partner with all major pharma companies. Let's say the 20 biggest ones have a sort of recurring business relationship with them. Standing purchase orders where they can send us ten molecules or so per year. And then we would get, you know, uh, a lot of molecules every year. This is our long-term target. We are still not there, but we have seen more multi-API deals with large pharma, which can fluctuate. But our target is to reach a situation where all the major companies send us new molecules every year. And one example we have now been emphasizing is that if anybody has a drug under development where they know the dosing will be above 100mg, they should consider Nanoform instead of, for example, spray drying, because if you have a dose above 100mg, you will encounter a problem with drug load. You might have too large a pill or too many pills by coming to Nanoform. All these projects, especially Amorphous Solid Dispersions (ASDs) with more than 100mg, should utilize Nanoform. And this is one example where we could see really nice growth in the coming years.

Christian Glennie
48:46 - 49:20

Thank you. Perhaps we should consider the revenue progression from this point forward. You called out, you know, a return to growth here. But you know, sequentially, we have seen quarter-on-quarter growth throughout this year. Typically, the fourth quarter has been your best quarter. Maybe, maybe last year was a bit of an anomaly there. Um, you know, you'll get stuck into executing these new contracts and new projects. Um, so just wondering whether you would expect sequential growth in the fourth quarter for revenues versus Q3.

Edward Hæggström
49:20 - 50:02

Albert, IFRS is always a little bit tricky as it projects how many hours are used and so forth. But of course, our target is to have sequential growth in quarters and over the years. We need to move to a completely different level compared to where we are now. And that will happen when you move from non-GMP to GMP. The numbers are much higher, and also when we start to do these deals, we get all kinds of fees and milestones and so forth. So that is how we see it.

Christian Glennie
50:06 - 50:49

Thank you. Um, I guess then maybe regarding the pivotal trial for Nano Enzalutamide, what more can be said at this point. Thank you.

Edward Hæggström
50:50 - 51:48

Maybe I can start here. So it was about Nanoform and what kind of clinical trials to expect? First of all, we are working on nano Enzalutamide together with the consortium for now. And that means, of course, that all the costs are shared in four equal parts. Should the originator come in? Of course, there may be a very different setup when it comes to the clinical trials. The number of patients, I think, the best way of thinking about it is that this will follow a kind of standard pathway, meaning the numbers align with those seen in similar studies. I don't see anything which would make this very different in that sense. Then if we go with the originator, they will probably be able to lean on data that they have, which means that the number of patients enrolled or subjects enrolled could be smaller. I don't know, Peter, do you have any other comments on this?

Peter Hänninen
51:48 - 52:19

Yeah, maybe just to mention that the expectation is that this will actually be done in healthy volunteers via a bioequivalence study, as said, and following in principle the guidelines for these types of bioequivalence studies.

Edward Hæggström
52:19 - 53:28

And the final comment. So this will not be a very large study and it will not be very expensive. So we are talking about, if you think of it, a cost of around one million rather than five million, and of course, this would be divided among the four parties. Uh, we are, of course, also part of the negotiations with all potential partners is discussing whether there will be, or what kind of, signing fees or upfront payments, and what kind of payments for participating in the study costs? What kind of milestones for success, like positive outcomes, filings, or market authorizations? So this is all part of the negotiations with all the partners. But if you think of it from a cost point of view, we don't expect these product kernels to increase the cost very much for Nanoform in the coming, uh, quarters. And remember also that there are potentially other kinds of funding available for any kind of projects if we want to.

Christian Glennie
53:31 - 53:56

And as the final comment. So if I may interpret it, there could be a scenario in which the consortium and/or maybe just Nanoform decides that the sort of million or so for the trial seems doable either by yourselves or through the consortium. And then that would, you know, the results of that trial then strengthen your hand in potential partnering discussions. Is that a scenario that could play out?

Edward Hæggström
53:56 - 54:37

That is one positive possible scenario. But it might also be that we sign a few partners before we do the study and then a few partners after, depending on the circumstances. Some partners would like to have the study results before they sign. Others want to sign earlier and potentially at a slightly lower price. So this is very much dependent on the project and on the partners we are talking to. And they all have different preferences. And we need to make this mosaic, considering that we have multiple products, multiple regions, and multiple partners we talk to.

Christian Glennie
54:40 - 55:24

And the final comment. And then maybe one final one. Maybe just on the commercial side. Um, you seem to be indicating that you could effectively have multiple partners in multiple markets or multiple geographies. I mean, that would, you know, typically most companies would look for maybe trying to get one single partner at least to cover Europe and maybe a different one for the US as it sort of reduces the complexity of those relationships and maybe gets stronger partner buy-in to driving that franchise. I'm just curious. Um, you know, if I'm missing anything about the benefits of having multiple partners in multiple markets.

Edward Hæggström
55:24 - 56:10

So if you think of it from a market to market perspective, there are local champions who have older, for example, oncology doctors in one country. And then you have another one where you have a different company that is the local champion, and then you have these larger companies that might be interested in the entirety of Europe, but they don't have the close connections to all the oncologists or urologists. So that means we want to find partners who have connections to oncologists and urologists in the major European markets, all five of them.

Christian Jones
56:10 - 57:02

But maybe if I could just add, and it's an important point to note, Christian, that we're not planning to launch this product as just a standard generic that gets prescribed or switched by the pharmacist. Um, the idea here is that there would be a product detailing team that would effectively sell the product to the specialists, the urology or prostate cancer specialists in the individual markets to show the differentiation and the value that the product can deliver for patients. And that's a slightly different strategy than just a very standard generic product play. That's why it's important to identify who can really drive those valuable discussions within each particular territory.

Edward Hæggström
57:03 - 58:13

Christian, I could add here that your question is spot on. It's the boon, but it's also the curse of having a valuable platform technology. It allows you to have many different initiatives going on at the same time. And here, as part of the mosaic that I talked about an hour ago, we are now in the fortunate situation that we need to figure out together during the conversations and together with ourselves. In what order and how to cadence and sequence the deals that are in front of us, both those that are already sort of on the table and those that will be entering onto the table. This is a very nice task. It's a complicated task. But the good news is it's something that has been done before, and we are going to have a very clear-cut, hopefully clever approach to it, where we try to minimize the level of complexity while still being able to drive out the platforms as effectively as we can.

Christian Glennie
58:17 - 58:19

Great. Thanks, guys. Thanks for taking the question.

Operator
58:23 - 58:27

The next question comes from Christopher from CIB. Please go ahead.

Christopher Udeh
58:30 - 59:19

Hi again. Thanks for taking another question. I was just wondering in terms of the slide, I guess it's slide 25, you have 21 projects on there, and you've had a total of 88 project signings to date. So, you know, maybe I missed this. Are these 21 projects all the ones that are still underway, perhaps those you've successfully pursued, and there's still interest to continue forward, and what happened to the others? Is it simply the, you know. Yeah. And what can you say about that?

Unknown 1
59:19 - 59:19

Thanks.

Edward Hæggström
59:19 - 59:57

So this is a slide where we, on the previous slide, showed that there is a very broad therapy area among the projects we have, and also that they are in different phases. This new slide is one where we show the broadness of the formulation challenge. But these are not necessarily the ones that we are working on right now. But this is more to show that the formulation challenge can be very different between the different projects. Peter, do you want to add anything to this?

Peter Hänninen
59:58 - 60:00

Nothing to add from Sir.

Christian Jones
60:04 - 60:06

Yeah, I concur. With what? With what Albert said.

Christopher Udeh
60:09 - 60:15

So it's not that they may. We shouldn't assume that all of these are necessarily active any longer.

Edward Hæggström
60:16 - 60:47

No. And you shouldn't assume that they will all continue either. Also remember that when we have had successful projects, they can be dormant for a while and then they can come back. So this is also something that we are learning, that projects can pause due to funding situations with biotechs or so forth. We have completed the POC, and now they are waiting for funding to resume progress. So, this is a fluid situation in that sense.

Christopher Udeh
60:50 - 60:51

Great. Thanks so much.

Operator
60:56 - 61:03

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Henry von Hartmann
61:05 - 61:22

Nothing to add from this side. Operator. On behalf of Nanoform, I would like to thank all participants for today. If you have any more questions, then please do reach out to us and we wish everybody a great Monday afternoon and evening. Thank you and goodbye.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…